1 / 49

Everyday Preparedness for the Challenges of FDA-Regulated Research

Everyday Preparedness for the Challenges of FDA-Regulated Research. Pat Ward & Diane Wilson UMMS Regulatory Affairs With special thanks to Kara Morgenstern, HSLO. Human Subject Research at UM. All – Governed by University policy See UM HRPP OM at http://www.hrpp.umich.edu

Download Presentation

Everyday Preparedness for the Challenges of FDA-Regulated Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Everyday Preparedness for the Challenges of FDA-Regulated Research Pat Ward & Diane Wilson UMMS Regulatory Affairs With special thanks to Kara Morgenstern, HSLO

  2. Human Subject Research at UM • All – Governed by University policy • See UM HRPP OM at http://www.hrpp.umich.edu • Most – Under OHRP jurisdiction • Common Rule, etc. at http://www.hhs.gov/ohrp/ • Some – Under FDA jurisdiction • Various regulations and guidance, start at http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm • Others – DoD, DoEd, etc.

  3. Important Themes for Today • Clinical research is a good thing for UMMS and its patients • UMMS clinical research is a part of the University’s overall HRPP program • FDA-regulated research as a Clinical Investigator team is hard • FDA-regulated research as a SPONSOR-Investigator team is VERY Hard • Compliant research takes infrastructure, supervision, and commitment • Mistakes happen • FDA investigators are VERY good at their jobs - if there are mistakes or concerns, the FDA will find them • Most mistakes and concerns can be satisfactorily addressed • Proactive preparations can help avoid mistakes and improve an inspection’s outcome • Advice and assistance are available!

  4. Responsibilities

  5. Responsibilities of Clinical Investigators and their teams • Follow investigational plan • Obtain and document informed consent • Clinical investigator personally conducts or supervises the investigation • Protect rights, safety, and welfare of participants • Ensure adequate medical care for the study participants • Obtain and maintain necessary approvals from IRB • Maintain and retain drug/device disposition • Maintain documentation of patient case history records • Provide written reports to the IRB and sponsor, as required • Ensure changes are not implemented without prior IRBand sponsor approval • Promptly report serious adverse events to the IRBand sponsor • Furnish progress and other reports, as required • Ensure all study team members are informed about their obligations noted above

  6. Additional Responsibilities of Sponsor-Investigators (a.k.a. IND/IDE Holders) • Select qualified clinical investigators • Secure written agreements and financial disclosures • Provide information to other investigators and study staff to ensure study performed properly • Ensure proper monitoring of the study • Ensure the study is performed in accordance with the investigational plan • Submit necessary amendments/supplements to FDA • Ensure that FDA and investigators are promptly informed of significant new adverse effects or risks • Maintain adequate records • Maintain proper control of the study drug/device

  7. Sponsor-Investigators assume both piles of responsibilities Responsibilities of Clinical Investigators Investigator Responsibilities Sponsor Responsibilities

  8. FDA History at UM

  9. FDA Inspections at UM

  10. Possible FDA Determinations • NAI – No Action Indicated • VAI – Voluntary Action Indicated • OAI – Official Action Indicated • Untitled Letter • Warning Letter • NIDPO Letter • “Notice of Initiation of Disqualification Proceedings and Opportunity to Explain”

  11. UM FDA Investigations NAI 25% OAI NAI VAI VAI No recent OAI Determinations!

  12. FDA observations at UM

  13. Clinical Investigator 483 Observations at UM (N=21 since 2008) • Investigation was not conducted in accordance with the investigational plan (11) • Failure to prepare or maintain adequate case histories with respect to data pertinent to the investigation (9) • Inadequate IRB approval or notification (8) • Problems with informed consent (7) • Control of investigational drug or device, or inadequate return of unused drug or drug disposition records inadequate (5)

  14. Clinical Investigator 483 Observations at UM (N=21 since 2008) • Protocol adherence • Unreported/unapproved changes • Protocol deviations/violations • Ineligible subjects • Informed consent • Missing • Wrong version • Signature/date irregularities • Misleading/overly technical language

  15. Clinical Investigator 483 Observations at UM (N=21 since 2008) • Documentation deficiencies • Incomplete/inaccurate CRFs • Missing source documents • Corrections not auditable • Missing or delayed IRB approval/reporting • Amendment implemented before approval • Missing or late reports • Lapse in IRB approval

  16. Auditable = ALCOA

  17. Clinical Investigator 483 Observations at UM (N=21 since 2008) • Poor test article accountability • Missing or delayed reports to sponsor • AEs and protocol deviations • Special issues for FDA Sponsor-Investigators • Inadequate monitoring • Missing or delayed reports to FDA

  18. OAI Example : BUSY Clinician & Clinical Investigator

  19. Busy clinician ends up with multiple “observations” on a Form 483 • Failure to obtain informed consent • Failure to follow investigational plan • Failure to report all changes to the IRB

  20. Built a Robust CAPA • PI self-imposed moratorium on clinical research • Certification training in FDA’s Clinical Investigator course • Adopt departmental QA program • New QA position • Enhanced SOPs • Documented training to SOPs • Weekly supervisory meetings with study team • Experienced colleague serving in advisory/mentor capacity • Oversight committee • Re-allocated some industry studies to other faculty • Successful external audit required before research allowed to resume • Prepare for FDA follow-up inspection

  21. General Lessons Learned:

  22. “All men make mistakes, but only WISE men learn from their mistakes” Winston Churchill

  23. FDA-Regulated Research… Top Tips for Everyday Preparedness From lessons we learned the hard way

  24. #1 Train Well • Take advantage of training opportunities and resources • PEERRS, IRB courses, MICHR courses, sponsor training, FDA’s on-line modules and Clinical Investigator Training Program, etc. • Consider steps toward certification by a professional organization (SOCRA, ACRP, etc.) • Seek an experienced mentor • If you don’t know (or don’t know that you don’t know) -- ASK!

  25. #2 Help Your PI Supervise Well • Communicate frequently with/between team members • Spot-check for quality of work – swap with another team for “fresh eyes” • Identify and resolve confusion, problems, etc. • Stay organized and current on documentation The buck may stop at the PI’s desk, but s/he needs your support to stay ahead of potential problems

  26. #3 Qualifications of Study Team • Identify all qualified Co-Is and staff needed and complete paperwork • Are study team members properly credentialed to complete medical procedures in protocol? • Has all training (including study-specific training) of study team members been completed and documented? • Are Co-Is on the FDA 1572 (drug study) or investigator agreement (device study), if applicable? • Is the delegation log accurate and up-to-date? • Are any conflicts of interests identified and managed?

  27. #4 Have a well-written,“doable” protocol How will you know? Doable Protocol Failure to follow the investigational plan

  28. #5 Test Run Protocol, Documents, and Other Systems • Are protocol procedures and timing feasible? • Are there inconsistencies between protocol, CRFs, investigator brochure, other study tools? • Do alerts and alarms work? If not…

  29. #6 Once You Commit to a Protocol… If you feel like something is outside the bounds, speak up! The protocol is not just a “guideline”

  30. #7 Implement Controls for Study Article Accountability • Study Drug Have you defined the roles and responsibilities for the Research Pharmacy? • PI may delegate actions, but retains ultimate responsibility • Study Device Are all components of the investigational device strictly tracked and controlled (locked down) to avoid access by unauthorized users?

  31. #8 Use Study Monitors Effectively • Whether a S-I or CI industry trial, ask yourself: • Can I rely on my monitor? • Does sponsor/monitor’s advice make sense? • Does my regulatory file document directions given by sponsor/monitor and addressed by my team?

  32. #9 Document To Tell Entire Story Ask yourself: • If you ran off to the Fiji Islands, would the documentation you left behind tell the entire story? • Why you deviated from the protocol? • Who from sponsor approved the deviation? • When and why a CRF value was corrected? • Who made the changes? • Why any CRF data are inconsistent with source documents?

  33. #10 Ongoing Quality Assessment • Know how things are going! Share this with your PI! • Has there been staff turnover? • Are research participants withdrawing or complaining? • Are IRB submissions of good quality and submitted timely? • What is outcome of monitoring reports? • What is outcome of In-house audits reports? • Office of Human Research Compliance Review (OHRCR) • If issues are arising. . . • Consider putting the project on holdto protect participants and data integrity • Report to IRB • Conduct root cause analysis (“5 Whys”) • Implement corrective and preventive actions

  34. Will FDA Inspection lightning strike you?

  35. Objectives of FDA Inspections • FDA Biomedical Monitoring (BIMO) Program Objectives • To protect the rights, safety, and welfare of subjects • To verify the accuracy and reliability of clinical trial data • To assess compliance with FDA's regulations governing the conduct of clinical trials

  36. Triggers for FDA Inspections • PI conducts many studies • PI is high enroller • Rapid or late enrollment • Pivotal trial for new drug application • Test article of focused FDA interest • PI conducts study outside his/her specialty area • Inconsistent data or unusual safety profile • Complaints • Non-compliance reported to FDA

  37. When FDA Calls (or appears)… • Inspections are usually scheduled in advance • 7-10 days notice • Will try to accommodate research team’s schedule • Before the call comes: • Prep anyone who might take that call • During the call, also politely ask: • Reason for inspection (data audit, for-cause, particular study?) • Names of inspectors coming • What would they like prepared in advance • After the call -- call us! • RA and/or IRBMED • We are prepared to advise/assist you

  38. What Do FDA Inspectors Do? • Hold you to… • FDA regulations • Sponsor’s protocol • IRB approval • Your own (and University) policies and procedures Keep to the code. The code is the law…

  39. What do FDA Inspectors Do? • Compare CRFs to source documents to verify… • Subjects met inclusion/exclusion criteria • IRB review/approval obtained • Informed consent obtained from subjects • Study was conducted according to the protocol • Primary efficacy measures • Adverse events reported • Safety data (labs, etc.) • Accountability of investigational agent

  40. What do FDA Inspectors Do? • Interview members of the study team and key institutional representatives (IRB, etc.) • Who did what? • What was the practice/expectation at time X? • Do interviewees understand their respective responsibilities?

  41. FDA’s View of Principal Investigator A PI should…. • Live, breathe, and follow the protocol • Be actively and fully engaged in supervising study staff • Be attentive to subject safety and rights • Make required reports to IRB, sponsor, etc. • Ensure accurate, cleardocumentation that fully tells the story • “Get It” With FDA…. It’s all about the PI !

  42. When we inspire their confidence, the FDA can go from this… …to this!

  43. Internal Resources • IRBMED Guidancehttp://med.umich.edu/irbmed/guidance.htm • IRBMED Traininghttp://med.umich.edu/irbmed/education.htm • MICHR Traininghttp://www.michr.umich.edu/education • MICHR MIAP https://www.michr.umich.edu/services/regulatorysupport/miap •  PEERRS http://my.research.umich.edu/peerrs/

  44. More Internal Resources • Public Access Requirements (for gov’t funded research) http://orsp.umich.edu/nih/public/ • www.Clinicaltrials.gov Workshops • http://ttc.iss.lsa.umich.edu/ttc/?s=clinicaltrials.gov&submit=Search • Safe computing: • http://www.safecomputing.umich.edu/dataguide/

  45. External Resources • Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126553.pdf • FDA Running Clinical Trials Page http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm • Writing an Effective 483 Response (2009 FDA Presentation) http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM102921.pdf • FDA Warning Letters http://www.fda.gov/iceci/enforcementactions/warningletters/default.htm

  46. External Resources (continued) • WIRB Online Seminars (free) http://ie6.wirb.com/Pages/EducationServices.aspx • Importance of an effective corrective and preventive action program • How to survive an FDA inspection of your clinical trial site • Feasibility issues – should I agree to do this trial? • Many other topics • ICH Guideline E6: Good Clinical Practices http://www.fda.gov/downloads/Drugs/Guidances/ucm073122.pdf • CDRH Learn Courses http://www.fda.gov/training/cdrhlearn/default.htm

  47. Questions? Thank you

More Related